<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300364</url>
  </required_header>
  <id_info>
    <org_study_id>EC07/90093</org_study_id>
    <nct_id>NCT01300364</nct_id>
  </id_info>
  <brief_title>Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia</brief_title>
  <official_title>Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro de Investigación Biomédica en Red de Salud Mental</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Sant Joan de Déu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective: To assess the efficacy of two antidepressants of different pharmacological
      families: citalopram (Selective serotonin reuptake inhibitors, SSRI) and reboxetine
      (Norepinephrine Reuptake inhibitor, NRI) as adjunct treatments to risperidone and olanzapine
      for the treatment of negative symptoms of schizophrenia.

      Secondary objectives: To assess the efficacy of citalopram and reboxetine as adjunct
      treatments to risperidone and olanzapine for the treatment of cognitive symptoms of
      schizophrenia. To compare the efficacy of reboxetine and citalopram as adjunct treatments for
      the treatment of negative and cognitive symptoms of schizophrenia.

      Method: Multicentric, randomized double-blind clinical trial compared to placebo with a six
      months follow-up. A total of 249 patients with a diagnosis of schizophrenia (DSM-IV criteria)
      and significant negative symptoms, will be recruited in the 9 participating centres.
      Variables: sociodemographic and clinical variables (PANSS, SANS, CGI global, GAF,LSP,
      Hamilton scale, BACS)
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy end-point will be the change in the score of the PANSS negative subscale from baseline to follow-up assessment.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy endpoints will be the change in the scores of the total PANSS and all the other clinical, social and neuropsychological scales from baseline to follow-up evaluation.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">249</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>reboxetine (NRI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>citalopram (SSRI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reboxetine</intervention_name>
    <description>8mg/day.</description>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_label>citalopram (SSRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram (SSRI)</intervention_name>
    <description>30mg/day</description>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_label>reboxetine (NRI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia (DSM-IV criteria)

          -  Stable doses of antipsychotic medication (olanzapine, risperidone)for at least 60 days
             prior to study initiation

          -  Presence of significant negative symptoms (defined as one or more negative symptom
             score grater than 4 in the PANSS scale) (Kay 1987)

          -  Patients have to give written informed consent to participate in the study

        Exclusion Criteria:

          -  Patients with a substance abuse/dependence diagnosis in the previous six months.

          -  Mental Retardation.

          -  Patients taking antidepressant in the last 4 months before the trial.

          -  Patients taking other antipsychotic medication, except: sinquan 100, Entumine 40,
             Largactil 100 and Seroquel 200.

          -  Patients who score more than 20 in Hamilton Rating Scale for Depression.

          -  Pregnancy or lactation.

          -  Serious impaired kidney function.

          -  History of hemorrhagic disorders.

          -  Reboxetine or citalopram allergy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Judith Usall U R, DRA.</last_name>
    <phone>936002650</phone>
    <phone_ext>2356</phone_ext>
    <email>jusall@pssjd.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parc Sanitari Sant Joan de Déu</name>
      <address>
        <city>Sant Boi Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Usall</last_name>
      <phone>93 6002650</phone>
      <phone_ext>2356</phone_ext>
      <email>jusall@pssjd.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Judith Usall Rodié</name_title>
    <organization>Parc Sanitari Sant Joan de Déu</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Reboxetine</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 2, 2012</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>November 15, 2012</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>November 19, 2012</submitted>
    <returned>December 17, 2012</returned>
    <submitted>April 17, 2013</submitted>
    <returned>May 23, 2013</returned>
    <submitted>May 27, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>May 29, 2013</submitted>
    <returned>July 3, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

